Journal article icon

Journal article

Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer

Abstract:

Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates mu...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
ORCID:
0000-0001-7946-5609
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
More from this funder
Name:
Cancer Research UK
Grant:
23969
More from this funder
Name:
Breast Cancer Research Foundation
More from this funder
Name:
NIHR Oxford Biomedical Research Centre
More from this funder
Name:
Engineering and Physical Sciences Research Council
Publisher:
Cell Press
Journal:
Cell Metabolism More from this journal
Volume:
28
Issue:
5
Pages:
679-688.e4
Publication date:
2018-09-20
Acceptance date:
2018-08-24
DOI:
ISSN:
1550-4131
Pmid:
30244975
Language:
English
Keywords:
Pubs id:
pubs:864243
UUID:
uuid:a9320331-ae91-42bb-bc6d-1fcd4384e020
Local pid:
pubs:864243
Source identifiers:
864243
Deposit date:
2018-12-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP